# Regenerative Medicine
Latest news and articles about Regenerative Medicine
Total: 8 articles found
Chasing Immortality Underground: How China’s New Regulations Are Reshaping the Stem Cell Grey Market
China's implementation of Order No. 818 has forced the stem cell anti-aging industry into a secretive, high-priced grey market. Despite strict bans on charging for clinical trials, businesses are exploiting off-label drugs and private networks to meet the insatiable demand for longevity treatments among the elite.
Zhenghai Bio-tech Advances China’s Regenerative Frontier with Stem Cell Milestone
Zhenghai Bio-tech has reached the product validation phase for its human umbilical cord mesenchymal stem cell project. This milestone signifies a major step in the company's shift toward advanced cellular therapy and regenerative medicine.
Turning Back the Biological Clock: Cellular Reprogramming Braces for Human Trials
Partial cellular reprogramming, a biotechnology aimed at reversing the aging process by resetting cellular markers, is set to begin its first human clinical trials this year following promising results in animal models.
Stem Cell Breakthrough: Solving the Stability Puzzle in Type 1 Diabetes Treatment
Researchers at the Karolinska Institute have developed a technology to stabilize the production of insulin-secreting cells from human stem cells. This breakthrough addresses a major technical bottleneck in regenerative medicine, paving the way for more reliable and scalable stem cell treatments for Type 1 diabetes.
Regulatory Renaissance: How New Policy Orders are Unlocking China’s Stem Cell Ambitions
China is implementing a landmark regulatory overhaul to streamline the transition of stem cell research from hospital labs to clinical practice. Centered in Shanghai's Zhangjiang hub, this new policy framework aims to leverage real-world clinical data to establish global leadership in regenerative medicine while enforcing strict ethical and safety standards.
The Great Leap for Regenerative Medicine: Japan’s Regulatory Gamble Sparks a Global iPSC Race
The global iPSC therapy market has entered a critical clinical phase following Japan's landmark 2026 conditional approvals for heart failure and Parkinson's treatments. While breakthroughs in China and the US demonstrate the curative potential for chronic diseases, the industry must now solve the dual challenges of high manufacturing costs and regulatory safety monitoring.
Neural Rewiring: Shanghai Biotech Secures Global First with Dual US-China Approval for Epilepsy Cell Therapy
Shanghai's Yuesai Biotechnology has become the first company globally to receive IND approval from both the US FDA and China's CDE for an iPSC-derived cell therapy targeting refractory epilepsy, marking a major breakthrough in regenerative medicine.
China’s Fountain of Youth: The Dangerous Rise of the Underground Stem Cell Market
China is witnessing a surge in illegal stem cell infusions marketed as high-priced anti-aging treatments, often involving collusion between private firms and public hospital doctors. Despite costs reaching $55,000 per shot, there is no scientific evidence or regulatory approval for these therapies, posing significant health and financial risks to consumers.